Shin Jae Il, Bayry Jagadeesh
Department of Pediatrics; Yonsei University College of Medicine; Seoul, Korea.
Institut National de la Santé et de la Recherche Médicale; Unité 1138; Paris, France; Centre de Recherche des Cordeliers; Equipe 16- Immunopathology and therapeutic immunointervention; Université Pierre et Marie Curie - Paris 6; Paris, France; Université Paris Descartes; Paris, France.
Hum Vaccin Immunother. 2014;10(5):1404-5. doi: 10.4161/hv.27665. Epub 2014 Jan 8.
Aging process can affect T cell and antibody response to vaccination and an age-related decline in the expression of CD62L on CD8(+) T-lymphocyte is one of the important factors that contribute. A recent report demonstrated that percentage of CD3(+)CD8(+)CD62L(+) cells and CD8(+) T-lymphocyte microRNA-92a levels significantly decline with the age and were positively correlated. These results suggested that the age-related attrition of human naïve T cells could be connected to a reduced microRNA-92a in T-lymphocytes and downregulation of the microRNA-92a level might indicate exhaustion of naïve T-cells due to alteration of the immunologic condition with aging. Further studies are necessary to evaluate whether targeting microRNA-92a as microRNA mimics could be one of the therapeutic strategies in improving vaccine response in elderly.
衰老过程会影响T细胞和对疫苗接种的抗体反应，而CD8(+) T淋巴细胞上CD62L表达的年龄相关性下降是其中一个重要因素。最近一份报告表明，CD3(+)CD8(+)CD62L(+)细胞的百分比和CD8(+) T淋巴细胞微小RNA-92a水平会随着年龄增长而显著下降，且呈正相关。这些结果表明，人类初始T细胞的年龄相关性损耗可能与T淋巴细胞中微小RNA-92a减少有关，微小RNA-92a水平的下调可能表明随着年龄增长免疫状况改变导致初始T细胞耗竭。有必要进一步研究评估将微小RNA-92a作为微小RNA模拟物进行靶向治疗是否可能是改善老年人疫苗反应的治疗策略之一。
